

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 February 2010 (11.02.2010)

PCT

(10) International Publication Number
WO 2010/017179 A1

- (51) **International Patent Classification:**
A61K 31/426 (2006.01) *A61K 31/4453* (2006.01)
- (21) **International Application Number:**
PCT/US2009/052667
- (22) **International Filing Date:**
4 August 2009 (04.08.2009)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/086,090 4 August 2008 (04.08.2008) US
- (71) **Applicant (for all designated States except US):** **CHDI, INC.** [US/US]; 350 Seventh Ave., Suite 601, New York, NY 10001 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **WITYAK, John** [US/US]; 3377 Avenida Nieve, Carlsbad, CA 92009 (US). **TOLEDO-SHERMAN, Leticia, M.** [US/US]; 3015 Goldsmith Street, Santa Monica, CA 90405 (US). **LEEDS, Janet** [US/US]; 443 Dunsmore Court, Encinitas, CA 92024 (US). **DOMINGUEZ, Cella** [US/US]; 8606 Allenwood Road, Los Angeles, CA 90046 (US). **COURTNEY, Stephen, Martin** [GB/GB]; 43 Fawkner Way, Stanford in the Vale, Oxfordshire SN7 8FF (GB). **YARNOLD, Christopher, John** [GB/GB]; 9 Mowbray Road, Didcot, Oxfordshire OX11 8ST (GB). **DE AGUIAR PENA, Paula, Cristina** [PT/GB]; 22 Fallowfield Crescent, Madley Park, Witney, Oxfordshire OX28 1AF (GB). **SCHEEL, Andreas** [DE/DE]; Haselweg 7, D-25469 Halstenbek (DE). **WINKLER, Dirk** [DE/DE]; Vehrenkampstr. 8, D-22527 Hamburg (DE).
- (74) **Agent:** **GARRETT, Arthur, S.**; Finnegan, Henderson, Farabow, Garrett & Dunner LLP, 901 New York Avenue, N.W., Washington, DC 20001-4413 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report (Art. 21(3))

(54) **Title:** CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

(57) **Abstract:** Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.



WO 2010/017179 A1